Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK Positive Non-small Cell Lung Cancer”

158 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 158 results

Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Early research (Phase 1)Ended earlyNCT01121588
What this trial is testing

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Who this might be right for
Neoplasms Malignant
Pfizer 44
Not applicableStudy completedNCT02042105
What this trial is testing

A Prospective Epidemiologic Study of ALK-Positive NSCLC in China

Who this might be right for
Non-small-cell Lung Cancer
Guangdong Association of Clinical Trials 3,649
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Early research (Phase 1)Study completedNCT02959619
What this trial is testing

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Who this might be right for
Solid TumorNon-Small Cell Lung Cancer Metastatic
Betta Pharmaceuticals Co., Ltd. 48
Not applicableLooking for participantsNCT05122806
What this trial is testing

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie 100
Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT02513667
What this trial is testing

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
University of Texas Southwestern Medical Center 14
Not applicableAvailableNCT06834074
What this trial is testing

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Who this might be right for
Non Small Cell Lung CancerALK-positive Non-small Cell Lung Cancer (NSCLC)
Nuvalent Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06378892
What this trial is testing

Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Who this might be right for
Non Small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano 45
Not applicableStudy completedNCT06339554
What this trial is testing

Alectinib-induced Endocrine Toxicity

Who this might be right for
NSCLC Stage IV
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 98
Post-approval studies (Phase 4)Not Yet RecruitingNCT06893354
What this trial is testing

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Who this might be right for
NSCLC
The First Affiliated Hospital of Guangzhou Medical University 20
Early research (Phase 1)UnknownNCT03130881
What this trial is testing

Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.

Who this might be right for
Non-Small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company 60
Not applicableStudy completedNCT03727477
What this trial is testing

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

Who this might be right for
Non-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive
Intergroupe Francophone de Cancerologie Thoracique 291
Not applicableActive Not RecruitingNCT07556549
What this trial is testing

Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Who this might be right for
Non-Small Cell Lung Cancer ALK-positive
Pfizer 50
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06779539
What this trial is testing

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
West China Hospital 33
Large-scale testing (Phase 3)Active Not RecruitingNCT02201992
What this trial is testing

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Who this might be right for
ALK Gene RearrangementALK Gene TranslocationALK Positive+5 more
ECOG-ACRIN Cancer Research Group 166
Not applicableUnknownNCT06207292
What this trial is testing

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer

Who this might be right for
NSCLCNSCLC Stage IVOligometastatic Disease+9 more
Radiotherapy Oncology Centre "Santa Maria" Hospital 100
Not applicableUnknownNCT04317651
What this trial is testing

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerAdvanced CancerMetastatic Cancer
Fondazione Ricerca Traslazionale 500
Load More Results